Free Trial
→ Massive Data Leak Exposes 512,000-Line Code That Could Change Society Forever (From Chaikin Analytics) (Ad)tc pixel Free DYAI Stock Alerts

Dyadic International (DYAI) Competitors

Dyadic International logo
$0.75 -0.01 (-1.72%)
As of 05/7/2026 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

DYAI vs. CRDF, VRCA, IFRX, ASRT, and VTVT

Should you be buying Dyadic International stock or one of its competitors? The main competitors of Dyadic International include Cardiff Oncology (CRDF), Verrica Pharmaceuticals (VRCA), InflaRx (IFRX), Assertio (ASRT), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical products" industry.

How does Dyadic International compare to Cardiff Oncology?

Dyadic International (NASDAQ:DYAI) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Cardiff Oncology had 1 more articles in the media than Dyadic International. MarketBeat recorded 1 mentions for Cardiff Oncology and 0 mentions for Dyadic International. Dyadic International's average media sentiment score of 0.00 equaled Cardiff Oncology'saverage media sentiment score.

Company Overall Sentiment
Dyadic International Neutral
Cardiff Oncology Neutral

28.0% of Dyadic International shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 29.5% of Dyadic International shares are owned by company insiders. Comparatively, 7.7% of Cardiff Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Dyadic International has higher revenue and earnings than Cardiff Oncology. Dyadic International is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dyadic International$3.09M8.79-$7.36M-$0.25N/A
Cardiff Oncology$590K185.41-$45.85M-$0.69N/A

Dyadic International has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500.

Dyadic International currently has a consensus target price of $3.00, suggesting a potential upside of 302.68%. Cardiff Oncology has a consensus target price of $10.10, suggesting a potential upside of 531.25%. Given Cardiff Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Cardiff Oncology is more favorable than Dyadic International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dyadic International
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Cardiff Oncology
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Dyadic International has a net margin of -239.67% compared to Cardiff Oncology's net margin of -7,733.22%. Cardiff Oncology's return on equity of -82.01% beat Dyadic International's return on equity.

Company Net Margins Return on Equity Return on Assets
Dyadic International-239.67% -695.96% -78.24%
Cardiff Oncology -7,733.22%-82.01%-64.09%

Summary

Cardiff Oncology beats Dyadic International on 9 of the 15 factors compared between the two stocks.

How does Dyadic International compare to Verrica Pharmaceuticals?

Dyadic International (NASDAQ:DYAI) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Dyadic International has higher earnings, but lower revenue than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dyadic International$3.09M8.79-$7.36M-$0.25N/A
Verrica Pharmaceuticals$35.58M3.98-$17.89M-$1.58N/A

28.0% of Dyadic International shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 29.5% of Dyadic International shares are owned by company insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Dyadic International has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500.

In the previous week, Verrica Pharmaceuticals had 4 more articles in the media than Dyadic International. MarketBeat recorded 4 mentions for Verrica Pharmaceuticals and 0 mentions for Dyadic International. Verrica Pharmaceuticals' average media sentiment score of 0.33 beat Dyadic International's score of 0.00 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Dyadic International Neutral
Verrica Pharmaceuticals Neutral

Verrica Pharmaceuticals has a net margin of -50.27% compared to Dyadic International's net margin of -239.67%. Verrica Pharmaceuticals' return on equity of 0.00% beat Dyadic International's return on equity.

Company Net Margins Return on Equity Return on Assets
Dyadic International-239.67% -695.96% -78.24%
Verrica Pharmaceuticals -50.27%N/A -40.08%

Dyadic International currently has a consensus target price of $3.00, suggesting a potential upside of 302.68%. Verrica Pharmaceuticals has a consensus target price of $17.00, suggesting a potential upside of 106.31%. Given Dyadic International's stronger consensus rating and higher possible upside, equities research analysts clearly believe Dyadic International is more favorable than Verrica Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dyadic International
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Verrica Pharmaceuticals
2 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.75

Summary

Verrica Pharmaceuticals beats Dyadic International on 9 of the 16 factors compared between the two stocks.

How does Dyadic International compare to InflaRx?

InflaRx (NASDAQ:IFRX) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

Dyadic International has higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InflaRx$30K6,385.62-$51.63M-$0.76N/A
Dyadic International$3.09M8.79-$7.36M-$0.25N/A

42.4% of InflaRx shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 16.3% of InflaRx shares are held by company insiders. Comparatively, 29.5% of Dyadic International shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

InflaRx has a beta of 2.42, meaning that its stock price is 142% more volatile than the S&P 500. Comparatively, Dyadic International has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

In the previous week, InflaRx had 15 more articles in the media than Dyadic International. MarketBeat recorded 15 mentions for InflaRx and 0 mentions for Dyadic International. InflaRx's average media sentiment score of 0.71 beat Dyadic International's score of 0.00 indicating that InflaRx is being referred to more favorably in the media.

Company Overall Sentiment
InflaRx Positive
Dyadic International Neutral

InflaRx has a net margin of 0.00% compared to Dyadic International's net margin of -239.67%. InflaRx's return on equity of -83.58% beat Dyadic International's return on equity.

Company Net Margins Return on Equity Return on Assets
InflaRxN/A -83.58% -62.04%
Dyadic International -239.67%-695.96%-78.24%

InflaRx presently has a consensus target price of $5.80, suggesting a potential upside of 118.87%. Dyadic International has a consensus target price of $3.00, suggesting a potential upside of 302.68%. Given Dyadic International's higher possible upside, analysts clearly believe Dyadic International is more favorable than InflaRx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InflaRx
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Dyadic International
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Summary

InflaRx beats Dyadic International on 10 of the 16 factors compared between the two stocks.

How does Dyadic International compare to Assertio?

Assertio (NASDAQ:ASRT) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

Assertio presently has a consensus target price of $19.90, suggesting a potential downside of 11.04%. Dyadic International has a consensus target price of $3.00, suggesting a potential upside of 302.68%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts clearly believe Dyadic International is more favorable than Assertio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Assertio
1 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Dyadic International
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Dyadic International has lower revenue, but higher earnings than Assertio. Assertio is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Assertio$118.71M1.22-$30.38M-$4.86N/A
Dyadic International$3.09M8.79-$7.36M-$0.25N/A

Assertio has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500. Comparatively, Dyadic International has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

49.0% of Assertio shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 5.7% of Assertio shares are held by company insiders. Comparatively, 29.5% of Dyadic International shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Assertio had 7 more articles in the media than Dyadic International. MarketBeat recorded 7 mentions for Assertio and 0 mentions for Dyadic International. Assertio's average media sentiment score of 0.48 beat Dyadic International's score of 0.00 indicating that Assertio is being referred to more favorably in the media.

Company Overall Sentiment
Assertio Neutral
Dyadic International Neutral

Assertio has a net margin of -25.59% compared to Dyadic International's net margin of -239.67%. Assertio's return on equity of -30.26% beat Dyadic International's return on equity.

Company Net Margins Return on Equity Return on Assets
Assertio-25.59% -30.26% -10.59%
Dyadic International -239.67%-695.96%-78.24%

Summary

Dyadic International beats Assertio on 9 of the 16 factors compared between the two stocks.

How does Dyadic International compare to vTv Therapeutics?

Dyadic International (NASDAQ:DYAI) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

Dyadic International presently has a consensus target price of $3.00, suggesting a potential upside of 302.68%. vTv Therapeutics has a consensus target price of $53.00, suggesting a potential upside of 70.75%. Given Dyadic International's higher probable upside, equities research analysts clearly believe Dyadic International is more favorable than vTv Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dyadic International
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
vTv Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

Dyadic International has higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dyadic International$3.09M8.79-$7.36M-$0.25N/A
vTv Therapeutics$1.02M119.90-$26.97M-$3.35N/A

Dyadic International has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, vTv Therapeutics has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500.

28.0% of Dyadic International shares are held by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are held by institutional investors. 29.5% of Dyadic International shares are held by insiders. Comparatively, 4.2% of vTv Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, vTv Therapeutics had 2 more articles in the media than Dyadic International. MarketBeat recorded 2 mentions for vTv Therapeutics and 0 mentions for Dyadic International. Dyadic International's average media sentiment score of 0.00 equaled vTv Therapeutics'average media sentiment score.

Company Overall Sentiment
Dyadic International Neutral
vTv Therapeutics Neutral

vTv Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -239.67%. vTv Therapeutics' return on equity of -73.76% beat Dyadic International's return on equity.

Company Net Margins Return on Equity Return on Assets
Dyadic International-239.67% -695.96% -78.24%
vTv Therapeutics N/A -73.76%-43.53%

Summary

Dyadic International beats vTv Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Dyadic International News Delivered to You Automatically

Sign up to receive the latest news and ratings for DYAI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DYAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DYAI vs. The Competition

Export
MetricDyadic InternationalMED IndustryMedical SectorNASDAQ Exchange
Market Cap$27.70M$3.45B$6.30B$12.15B
Dividend YieldN/A2.23%2.77%5.24%
P/E Ratio-2.9833.4528.7027.01
Price / Sales8.79294.60528.9177.57
Price / CashN/A125.2843.3053.97
Price / Book24.837.309.866.89
Net Income-$7.36M$23.67M$3.55B$333.11M
7 Day PerformanceN/AN/AN/A0.14%
1 Month Performance-16.55%4.95%5.19%6.79%
1 Year Performance-31.02%75.81%40.36%38.93%

Dyadic International Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DYAI
Dyadic International
2.1328 of 5 stars		$0.75
-2.0%		$3.00
+302.7%		-31.7%$27.70M$3.09MN/A7
CRDF
Cardiff Oncology
0.9376 of 5 stars		$1.68
-2.3%		$10.10
+501.2%		-35.7%$117.60M$590KN/A20
VRCA
Verrica Pharmaceuticals
1.618 of 5 stars		$6.53
-4.3%		$17.00
+160.3%		+102.5%$117.25M$35.58MN/A40
IFRX
InflaRx
3.7876 of 5 stars		$1.67
+3.7%		$5.80
+247.3%		+82.1%$116.39M$30KN/A60
ASRT
Assertio
2.2869 of 5 stars		$18.04
flat		$18.00
-0.2%		+141.7%$116.27M$118.71MN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:DYAI) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners
Massive Data Leak Exposes 512,000-Line Code That Could Change Society Forever
"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...
Chaikin Analytics | Sponsoredtc pixel
Why I flew on a tiny helicopter next to a potential nuclear bomb target
Satellite Confirms: Elon Musk Activating Strange 'Dark Energy' Across U.S. South Confirmed by satellites 30...
Altimetry | Sponsoredtc pixel
Elon’s AI supercomputer just went live. Here’s my #1 stock.
Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...
InvestorPlace | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Is the SpaceX IPO “Rigged?”
The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...
The Oxford Club | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel